190 related articles for article (PubMed ID: 22184763)
21. Coming to grips with hand-foot syndrome. Insights from clinical trials evaluating capecitabine.
Scheithauer W; Blum J
Oncology (Williston Park); 2004 Aug; 18(9):1161-8, 1173; discussion 1173-6, 1181-4. PubMed ID: 15471200
[TBL] [Abstract][Full Text] [Related]
22. A polymorphism in the cytidine deaminase promoter predicts severe capecitabine-induced hand-foot syndrome.
Caronia D; Martin M; Sastre J; de la Torre J; García-Sáenz JA; Alonso MR; Moreno LT; Pita G; Díaz-Rubio E; Benítez J; González-Neira A
Clin Cancer Res; 2011 Apr; 17(7):2006-13. PubMed ID: 21325291
[TBL] [Abstract][Full Text] [Related]
23. [Capecitabine-induced hyperpigmentation].
Vázquez-Bayo C; Rodríguez-Bujaldón AL; Jiménez-Puya R; Galán-Gutiérrez M; Moreno-Giménez JC
Actas Dermosifiliogr; 2007 Sep; 98(7):491-3. PubMed ID: 17669305
[TBL] [Abstract][Full Text] [Related]
24. Study of low-dose capecitabine monotherapy for metastatic breast cancer.
Taguchi T; Nakayama T; Masuda N; Yoshidome K; Akagi K; Nishida Y; Yoshikawa Y; Ogino N; Abe C; Sakamoto J; Noguchi S;
Chemotherapy; 2010; 56(2):166-70. PubMed ID: 20407245
[TBL] [Abstract][Full Text] [Related]
25. Capecitabine and hand-foot syndrome.
Saif MW
Expert Opin Drug Saf; 2011 Mar; 10(2):159-69. PubMed ID: 21174613
[TBL] [Abstract][Full Text] [Related]
26. [Hand-foot syndrome induced by chemotherapy: a case study].
Simão DA; Lima ED; Souza RS; Faria TV; Azevedo GF
Rev Bras Enferm; 2012; 65(2):374-8. PubMed ID: 22911424
[TBL] [Abstract][Full Text] [Related]
27. Reduced dose capecitabine is an effective and well-tolerated treatment in patients with metastatic breast cancer.
El-Helw L; Coleman RE
Breast; 2005 Oct; 14(5):368-74. PubMed ID: 16216738
[TBL] [Abstract][Full Text] [Related]
28. Uncontrolled hypertriglyceridemia induced by capecitabine: case report and review of the literature.
Bar-Sela G; Haim N
Cancer Chemother Pharmacol; 2009 Apr; 63(5):779-82. PubMed ID: 18641989
[TBL] [Abstract][Full Text] [Related]
29. Unilateral hand-foot syndrome: does it take sides? Case report and literature review.
Almeida da Cruz L; Hoff PM; Ferrari CL; Riechelmann RS
Clin Colorectal Cancer; 2012 Mar; 11(1):82-4. PubMed ID: 21764392
[No Abstract] [Full Text] [Related]
30. The Effect of Pyridoxine for Prevention of Hand-Foot Syndrome in Colorectal Cancer Patients with Adjuvant Chemotherapy Using Capecitabine: A Randomized Study.
Ota M; Tatsumi K; Suwa H; Watanabe J; Watanabe K; Osada S; Tanaka K; Shoichi F; Ichikawa Y; Kunisaki C; Endo I
Hepatogastroenterology; 2014 Jun; 61(132):1008-13. PubMed ID: 26158157
[TBL] [Abstract][Full Text] [Related]
31. Actinic keratosis and capecitabine therapy.
Higa GM; Kovach RF; Abraham J
J Oncol Pharm Pract; 2005 Dec; 11(4):151-3. PubMed ID: 16595067
[TBL] [Abstract][Full Text] [Related]
32. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
Aprile G; Mazzer M; Moroso S; Puglisi F
Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
[TBL] [Abstract][Full Text] [Related]
33. Moderate dose capecitabine in older patients with metastatic breast cancer: a standard option for first line treatment?
Kotsori AA; Noble JL; Ashley S; Johnston S; Smith IE
Breast; 2010 Oct; 19(5):377-81. PubMed ID: 20392643
[TBL] [Abstract][Full Text] [Related]
34. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving capecitabine as adjuvant chemotherapy.
Son HS; Lee WY; Lee WS; Yun SH; Chun HK
Yonsei Med J; 2009 Dec; 50(6):796-802. PubMed ID: 20046420
[TBL] [Abstract][Full Text] [Related]
35. Effect of modified taohongsiwu decoction on patients with chemotherapy-induced hand-foot syndrome.
Zhao C; Chen J; Yu B; Wu X; Dai C; Zhou C; Chen X
J Tradit Chin Med; 2014 Feb; 34(1):10-4. PubMed ID: 25102684
[TBL] [Abstract][Full Text] [Related]
36. [Therapy traces on hands and feet in a patient with colon cancer].
Stiefelhagen P
MMW Fortschr Med; 2012 Jun; O 154 Suppl 2():9. PubMed ID: 22916416
[No Abstract] [Full Text] [Related]
37. [Adjuvant chemotherapy with capecitabine for colon cancer - a case series].
Kuji M; Masuko H; Yamagami H; Matsumoto S; Tanioka T; Takahashi S; Ishizu H; Takahashi M
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1752-4. PubMed ID: 25731318
[TBL] [Abstract][Full Text] [Related]
38. Onycholysis with the appearance of a "sunset" secondary to capecitabine.
Maino KL; Norwood C; Stashower ME
Cutis; 2003 Sep; 72(3):234-6. PubMed ID: 14533836
[TBL] [Abstract][Full Text] [Related]
39. [A case of local-recurring breast cancer under long term-treatment by capecitabine].
Yoneyama K; Takeshita T; Suzuki H; Morise M; Suzuki T; Kishi S; Tsutsui A; Matsumoto A
Gan To Kagaku Ryoho; 2011 Dec; 38(13):2623-5. PubMed ID: 22189229
[TBL] [Abstract][Full Text] [Related]
40. An open-label, multicenter study of outpatient capecitabine monotherapy in 631 patients with pretreated advanced breast cancer.
Venturini M; Paridaens R; Rossner D; Vaslamatzis MM; Nortier JW; Salzberg M; Rodrigues H; Bell R
Oncology; 2007; 72(1-2):51-7. PubMed ID: 18004077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
